Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimepinostat in advanced solid tumors
NCT02307240Phase 1Completed
- Sponsor
- Curis, Inc.
- Start
- Nov 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fimepinostat in solid tumor, NUT carcinoma (NMC), triple-negative breast cancer (TNBC) and 1 more, sponsored by Curis, Inc. Primary endpoint: Safety and Tolerability. Started Nov 2014; status: completed.
02
Drugs
fimepinostat
03
Conditions
solid tumorNUT carcinoma (NMC)triple-negative breast cancer (TNBC)High-Grade Serous Ovarian Carcinoma (HGSOC)
Beyond the preview
Go deeper on NCT02307240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307240.